Larvol Delta - Avadel-Pharmaceuticals-completes-enrollment-in-the-RESTON-phase-3-pivotal-trial-of-FT218-for-excessive-daytime-sleepiness-and-cataplexy-in-patients-with-narcolepsy

sodium oxybate ER (FT218) - Avadel

https://www.globenewswire.com/news-release/2019/12/17/1961513/0/en/Avadel-Pharmaceuticals-Completes-Enrollment-in-the-REST-ON-Phase-3-Pivotal-Trial-of-FT218-for-Excessive-Daytime-Sleepiness-and-Cataplexy-in-Patients-with-Narcolepsy.html

Dec 17, 2019

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next